Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A limited access phase II trial of cetuximab (C225, NSC 714692) in combination with cisplatin (NSC 119875) in the treatment of advanced, persistent, or recurrent carcinoma of the cervix

Trial Profile

A limited access phase II trial of cetuximab (C225, NSC 714692) in combination with cisplatin (NSC 119875) in the treatment of advanced, persistent, or recurrent carcinoma of the cervix

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2014

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Mar 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top